发明名称 |
Compositions for treatment of attention deficit hyperactivity disorder |
摘要 |
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. |
申请公布号 |
US9283214(B2) |
申请公布日期 |
2016.03.15 |
申请号 |
US201514704836 |
申请日期 |
2015.05.05 |
申请人 |
Ironshore Pharmaceuticals & Development, Inc. |
发明人 |
Lickrish David;Zhang Feng |
分类号 |
A61K31/4458;A61K9/48;A61K9/50 |
主分类号 |
A61K31/4458 |
代理机构 |
Vinson & Elkins LLP |
代理人 |
Vinson & Elkins LLP |
主权项 |
1. A solid, oral pharmaceutical composition comprising:
a single population of beads, said beads comprising:a core comprising methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient;
a sustained release layer enclosing the core; and a delayed release layer enclosing the sustained release layer, wherein when the formulation is administered to a human subject in a fasted state, (i) there is a lag of at least 7 hours during which the plasma concentration of methylphenidate is less than 5% of the maximum plasma (Cmax), (ii) a plasma area under the curve at 10 hours (AUC0-10) after administration that is less than about 7% of AUC0-48; and (iii) wherein the time to Cmax (Tmax) is between 12 and 19 hours after administration, and wherein administration to a population of subjects provides a significant improvement in ADHD related behavior or cognitive ability over a period of at least 12 continuous hours as measured by a validated rating scale. |
地址 |
Camana Bay KY |